Immunic announces up to $400M private placement and board changes to fund MS trials

IMMUNIC, INC.

Gross proceeds of up to $400M from private placement led by BVF Partners, with $200M from pre-funded warrants at $0.873 each.
Proceeds to fund completion of Phase 3 ENSURE trials in relapsing MS and initiation of Phase 3 in primary progressive MS.
Simona Skerjanec appointed interim chair; Thor Nagel joins board; Maria Törnsén resigns.
Company entered into royalty purchase agreement with Series B warrant holders for 5% synthetic royalty on vidofludimus calcium sales.
Company plans to search for new CEO with commercial experience; Dr. Vitt to transition to senior scientific role.

item 1.01 item 3.02 item 8.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

IMMUNIC, INC. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $200 million (effective 2026-02-12).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $200 million
Effective: 2026-02-12

Exact text from the filing

On February 12, 2026, Immunic Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain accredited investors (the “ Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), pre-funded warrants

View on SEC.gov

306 material agreements filed in the last 30 days. Browse all material agreements →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-26-000129

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.